Page 4 - BLADDER CANCER
P. 4

Advanced Urothelial Carcinoma



                Current Treatment Landscape







                • First-line: Platinum-based chemotherapy



                       • Response rates 40-60%






                • Second-line: PD-1/PDL-1 Inhibitors


                       • Pembrolizumab has a survival benefit


                       • Durable responses occur, but only in a minority of patients







                • Coming soon: First-line maintenance therapy


                       • Avelumab in patients with stable disease / response to platinum-

                          based chemotherapy. (Health Canada approved, pending


                          access)
   1   2   3   4   5   6   7   8   9